Rigel Pharmaceuticals Inc. (RIGL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Rigel Pharmaceuticals Inc... (RIGL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

16.68

-0.43 (-2.51%)

At close: Jan 14, 2025, 3:59 PM

16.69

0.03%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	16.25
Market Cap	293.91M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.27
PE Ratio (ttm)	61.8
Forward PE	n/a
Analyst	Hold

Ask	20.96
Volume	186,743
Avg. Volume (20D)	259,096
Open	17.22
Previous Close	17.11
Day's Range	16.37 - 17.43
52-Week Range	7.48 - 29.82
Beta	undefined

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 29, 2000

Employees 147

Stock Exchange NASDAQ

Ticker Symbol RIGL

Website https://www.rigel.com

Analyst Forecast

According to 5 analyst ratings, the average rating for RIGL stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 49.84% from the latest price.

Buy 40.00%

Hold 60.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Rigel Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025, during market hours.
Analysts project revenue of $57.60M, reflecting a 60.93% YoY growth and earnings per share of 0.33.

Why Price Moved

1 month ago · Source

-11.23%

Rigel Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

2 months ago · Source

+9.1%

Rigel Pharmaceuticals shares are trading higher Citigroup maintained a Buy rating on the stock and raised its price target from $40 to $49.

News

6 days ago · zacks.com

Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks

We have picked five small-cap stocks that have strong growth potential for 2025. These are: TZOO, EVER, LIND, RIGL, GHM.

2 weeks ago · seekingalpha.com

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three appro...

3 weeks ago · zacks.com

Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.

1 month ago · zacks.com

How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%

The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive...

1 month ago · zacks.com

5 Relative Price Strength Options Available for Investors

RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength.

2 months ago · seekingalpha.com

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

2 months ago · zacks.com

Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago.